A Phase 1 interventional study of AZD4144 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-07.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Atherosclerosis by AstraZeneca — 1 open to participants now, 2 under way, 2 of them phase 3. Atherosclerosis · AstraZeneca.
Among the 21 studies in Atherosclerosis by AstraZeneca, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 in phase 1, and was the 19th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →1 of the 21 studies in Atherosclerosis by AstraZeneca is open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Brazil and 33 more countries
Ages 18+
By country, each count listing its studies:
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 84 across the 14 interventional studies, 1,024 across the 6 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in Atherosclerosis by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Atherosclerosis by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.
This is placebo-controlled, parallel group and single centre study in healthy male and female participants with obesity and no known Atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or Type 2 Diabetes Mellitus.
Participants will be randomized in the ratio of 1:1 to receive either AZD4144 or placebo.
This study will comprise of:
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of AZD4144 under fasted conditions once daily for 28 days.
Drug: AZD4144
Participants will receive a single oral dose of matching placebo to AZD4144 under fasted conditions once daily for 28 days.
Drug: Placebo
AZD4144 will be administered orally as per arms they have been assigned.
Placebo will be administered orally as per arms they have been assigned.
Number of Participants with Adverse Events (AEs)
The safety and tolerability of AZD4144 compared with placebo will be assessed.
Time frame: From Screening (Day -28 to Day -2) to final follow-up (Day 56)
Relative change from baseline in systemic interleukin-6 (IL-6) levels
The effect of AZD4144 on circulating inflammatory biomarker IL-6 compared with placebo will be assessed.
Time frame: From baseline to 4 weeks
Relative change from baseline in systemic IL-18 levels
The effect of AZD4144 compared with placebo on circulating biomarker IL-18 will be assessed.
Time frame: From baseline to 4 weeks
Relative change from baseline in high-sensitivity C-reactive protein (hsCRP) levels
The effect of AZD4144 compared with placebo on circulating biomarker hsCRP will be assessed.
Time frame: From baseline to 4 weeks
Observed lowest concentration before the next dose is administered (Ctrough) of AZD4144
The pharmacokinetics (PK) of AZD4144 in participants with obesity will be assessed.
Time frame: From Day 1 to Day 28
Maximum observed drug concentration (Cmax) of AZD4144
The PK of AZD4144 in participants with obesity will be assessed.
Time frame: From Day 1 to Day 28
Time to reach maximum observed concentration (tmax) of AZD4144
The PK of AZD4144 in participants with obesity will be assessed.
Time frame: From Day 1 to Day 28
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST /Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Sep 2025, 5 months.
Of 32 phase 1 interventional studies under Atherosclerosis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 41. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berzanoflast